Takeda Pharmaceutical Company Limited (TAK) Stock Analysis

Takeda is a nearly 245-year-old global biopharmaceutical company with JPY 4.51 trillion in revenue across GI, plasma-derived therapies, rare diseases, oncology, neuroscience, vaccines, and other products. Its sales are geographically diversified, led by the US at 49%. The company serves resilient chronic, complex, and rare disease markets where efficacy, safety, and continuity of care matter. While Vyvanse generic erosion weighs on results, Entyvio, PDT, and late-stage pipeline launches position Takeda for a transition toward higher-margin specialty growth.